{
  "data": [
    {
      "id": "1",
      "company": "Merck & Co Inc.",
      "ticker": "MRK",
      "drug": "KEYTRUDA",
      "pdufaDate": "2026-02-20",
      "description": "FDA decision on KEYTRUDA plus chemotherapy with or without bevacizumab for treatment of patients with platinum-resistant recurrent ovarian cancer",
      "category": "Oncology",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.338806"
    },
    {
      "id": "2",
      "company": "VANDA PHARMACEUTICALS",
      "ticker": "VNDA",
      "drug": "Bysanti",
      "pdufaDate": "2026-02-21",
      "description": "FDA decision on Bysanti (milsaperidone) for the acute treatment of bipolar I disorder and the treatment of schizophrenia",
      "category": "Neurology/Psychiatry",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.338992"
    },
    {
      "id": "3",
      "company": "Eton Pharmaceuticals, Inc",
      "ticker": "ETON",
      "drug": "ET-600",
      "pdufaDate": "2026-02-25",
      "description": "FDA decision on ET-600 for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency",
      "category": "Metabolic/Endocrine",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.339264"
    },
    {
      "id": "4",
      "company": "Otsuka Holdings Co., Ltd.",
      "ticker": "OTSKF",
      "drug": "INQOVI",
      "pdufaDate": "2026-02-25",
      "description": "FDA decision on INQOVI plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy",
      "category": "Oncology",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.339428"
    },
    {
      "id": "5",
      "company": "Sanofi SA",
      "ticker": "SNY",
      "drug": "Dupixent",
      "pdufaDate": "2026-02-28",
      "description": "FDA decision on Dupixent in adults and children aged 6 years and older with allergic fungal rhinosinusitis (AFRS).",
      "category": "Respiratory",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.339590"
    },
    {
      "id": "6",
      "company": "Regeneron Pharmaceuticals Inc",
      "ticker": "REGN",
      "drug": "Dupixent",
      "pdufaDate": "2026-02-28",
      "description": "FDA decision on Dupixent in adults and children aged 6 years and older with allergic fungal rhinosin",
      "category": "Other",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.339747"
    },
    {
      "id": "7",
      "company": "Ascendis Pharma A/S",
      "ticker": "ASND",
      "drug": "TransCon CNP",
      "pdufaDate": "2026-02-28",
      "description": "FDA decision on TransCon CNP (navepegritide) for the treatment of children with achondroplasia",
      "category": "Genetic/Rare Disease",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.339904"
    },
    {
      "id": "8",
      "company": "Biomarin Pharmaceutical Inc.",
      "ticker": "BMRN",
      "drug": "PALYNZIQ",
      "pdufaDate": "2026-02-28",
      "description": "FDA decision on PALYNZIQ to expand treatment to include adolescents aged 12-17 with phenylketonuria",
      "category": "Other",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.340054"
    },
    {
      "id": "9",
      "company": "Lantheus Holdings Inc.",
      "ticker": "LNTH",
      "drug": "New formulation of F18",
      "pdufaDate": "2026-03-06",
      "description": "FDA decision on new formulation of F18 PSMA-targeted PET imaging agent to determine the presence or absence of recurrent and/or metastatic prostate cancer.",
      "category": "Oncology",
      "status": "Pending",
      "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
      "scrapedAt": "2026-02-10T06:25:46.340221"
    }
  ],
  "meta": {
    "source": "RTTNews",
    "sourceUrl": "https://www.rttnews.com/corpinfo/fdacalendar.aspx",
    "scrapedAt": "2026-02-10T06:25:46.341415",
    "itemCount": 9,
    "dateRange": {
      "earliest": "2026-02-20",
      "latest": "2026-03-06"
    }
  }
}